LuMind welcomes three directors to team
In the beginning of 2025, following three nation-wide searches, LuMind IDSC welcomed new team members to the Administration, Community Engagement, and Development departments. Stephen Doyle, Amy Shapley-Farrell, and Deborah Still […]
Understanding key differences among Alzheimer’s clinical trials in Down syndrome
LuMind IDSC releases guide for families learning about Alzheimer’s disease therapies MARCH 14, 2025 – In anticipation of new opportunities for adults with Down syndrome to participate in clinical trials […]
RAND report shows benefit of investment in future health outcomes for adults with Down syndrome
10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome, New Report […]
RAND report shows benefit of investment in future health outcomes for adults with Down syndrome
10/1/2024 | For immediate release | Contact: Kate O’Neill ([email protected]) Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome, New Report […]
Updates from AAIC: Down syndrome community boosted by FDA confirmation of label and new anti-amyloid clinical trial
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla. At the 2024 Alzheimer’s Association International Conference in Philadelphia this […]
Updates from AAIC: Down syndrome community boosted by FDA confirmation of label and new anti-amyloid clinical trial
Information revealed at the 2024 AAIC conference on the ACTC-DS-led study in DS-associated Alzheimer’s disease with Lilly’s anti-amyloid drug Kisunla. At the 2024 Alzheimer’s Association International Conference in Philadelphia this […]
FDA issues approval for new Alzheimer’s drug Kisunla; Down syndrome community is optimistic
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and Drug Administration (FDA) announced the approval of Kisunla (donanemab), an […]
FDA issues approval for new Alzheimer’s drug Kisunla; Down syndrome community is optimistic
FDA issues approval for Kisunla, new Alzheimer’s drug; Down syndrome community optimistic On Tuesday, July 2, the U.S. Food and Drug Administration (FDA) announced the approval of Kisunla (donanemab), an […]
Down syndrome population will see a clinical trial of new Alzheimer’s drug
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome will be invited to participate in a clinical trial of […]
Down syndrome population will see a clinical trial of new Alzheimer’s drug
Major pharmaceutical company announces Down syndrome population will see a clinical trial of new Alzheimer’s drug People with Down syndrome will be invited to participate in a clinical trial of […]
